Kalaris Therapeutics Inc
$4.72
-3.7%Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.7).
Valuation inputs: P/E -1.7, earnings yield N/A, momentum -3.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -55.1%, ROIC -41.1%).
Profitability stack: net margin 0.0%, ROE -55.1%, ROIC -41.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +35.3%, momentum -3.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Kalaris Therapeutics Inc Market vs Earnings Trajectory
Loading price and EPS data...
Kalaris Therapeutics Inc Fair Value Envelope
No Revenue Data
KLRS has not reported any revenue values in the available annual periods.
Kalaris Therapeutics Inc Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
KLRS has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
KLRS has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
KLRS has not reported any net profit margin values in the available annual periods.
Kalaris Therapeutics Inc Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Kalaris Therapeutics Inc Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Kalaris Therapeutics Inc Street Expectations Map
Wall Street analysts project that KLRS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 18.25, with estimates ranging from a low of 14.00 to a high of 23.00.
The consensus 1-year price target stands at 18.25, with estimates ranging from a low of 14.00 to a high of 23.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Kalaris Therapeutics Inc Insider Positioning
During the last 12 months, insiders have purchased $7.35M and sold $13K worth of KLRS shares, resulting in $7.34M of net buying activity.
3 Months
244.3K
1.18M
1.9K
12.87K
+1.2M
+$1.17M
3-6 Months
479.8K
5.00M
0
0.00
+5.0M
+$5.00M
6-9 Months
235.0K
1.17M
0
0.00
+1.2M
+$1.17M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Akkaraju Srinivas
Director, 10 Percent Owner:
$6.18M
Gall Matthew
Officer: Chief Financial Officer
$1.17M
Top Sellers
Hagen Brett R
Officer: Chief Accounting Officer
$13K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $7.34M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
KLRS has not reported any dividend yield values in the available annual periods.
klrs Dividend History
Learning Layer
Related Guides
Build conviction on KLRS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.